These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 14693724)

  • 1. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
    Palmer JP; Fleming GA; Greenbaum CJ; Herold KC; Jansa LD; Kolb H; Lachin JM; Polonsky KS; Pozzilli P; Skyler JS; Steffes MW
    Diabetes; 2004 Jan; 53(1):250-64. PubMed ID: 14693724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
    Steffes MW; Sibley S; Jackson M; Thomas W
    Diabetes Care; 2003 Mar; 26(3):832-6. PubMed ID: 12610045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of beta cell function in type 1 diabetes mellitus.
    Vendrame F; Zappaterreno A; Dotta F
    Minerva Med; 2004 Apr; 95(2):79-84. PubMed ID: 15272242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual C-peptide in type 1 diabetes: what do we really know?
    VanBuecken DE; Greenbaum CJ
    Pediatr Diabetes; 2014 Mar; 15(2):84-90. PubMed ID: 24645775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes.
    Latres E; Greenbaum CJ; Oyaski ML; Dayan CM; Colhoun HM; Lachin JM; Skyler JS; Rickels MR; Ahmed ST; Dutta S; Herold KC; Marinac M
    Diabetes; 2024 Jun; 73(6):823-833. PubMed ID: 38349844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
    Ryan EA; Lakey JR; Rajotte RV; Korbutt GS; Kin T; Imes S; Rabinovitch A; Elliott JF; Bigam D; Kneteman NM; Warnock GL; Larsen I; Shapiro AM
    Diabetes; 2001 Apr; 50(4):710-9. PubMed ID: 11289033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in developing endpoints for type 1 diabetes intervention studies.
    Cernea S; Raz I; Herold KC; Hirshberg B; Roep BO; Schatz DA; Fleming GA; Pozzilli P; Little R; Schloot NC; Leslie RD; Skyler JS; Palmer JP;
    Diabetes Metab Res Rev; 2009 Nov; 25(8):694-704. PubMed ID: 19771545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft.
    Keymeulen B; Gillard P; Mathieu C; Movahedi B; Maleux G; Delvaux G; Ysebaert D; Roep B; Vandemeulebroucke E; Marichal M; In 't Veld P; Bogdani M; Hendrieckx C; Gorus F; Ling Z; van Rood J; Pipeleers D
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17444-9. PubMed ID: 17090674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year follow-up after clinical islet transplantation.
    Ryan EA; Paty BW; Senior PA; Bigam D; Alfadhli E; Kneteman NM; Lakey JR; Shapiro AM
    Diabetes; 2005 Jul; 54(7):2060-9. PubMed ID: 15983207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop.
    Rickels MR; Stock PG; de Koning EJP; Piemonti L; Pratschke J; Alejandro R; Bellin MD; Berney T; Choudhary P; Johnson PR; Kandaswamy R; Kay TWH; Keymeulen B; Kudva YC; Latres E; Langer RM; Lehmann R; Ludwig B; Markmann JF; Marinac M; Odorico JS; Pattou F; Senior PA; Shaw JAM; Vantyghem MC; White S
    Transplantation; 2018 Sep; 102(9):1479-1486. PubMed ID: 29528967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International trial of the Edmonton protocol for islet transplantation.
    Shapiro AM; Ricordi C; Hering BJ; Auchincloss H; Lindblad R; Robertson RP; Secchi A; Brendel MD; Berney T; Brennan DC; Cagliero E; Alejandro R; Ryan EA; DiMercurio B; Morel P; Polonsky KS; Reems JA; Bretzel RG; Bertuzzi F; Froud T; Kandaswamy R; Sutherland DE; Eisenbarth G; Segal M; Preiksaitis J; Korbutt GS; Barton FB; Viviano L; Seyfert-Margolis V; Bluestone J; Lakey JR
    N Engl J Med; 2006 Sep; 355(13):1318-30. PubMed ID: 17005949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
    Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2015; 15(16):1-84. PubMed ID: 26644812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent insulin secretion, assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement.
    Eff C; Faber O; Deckert T
    Diabetologia; 1978 Sep; 15(3):169-72. PubMed ID: 359394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients.
    Covic AM; Schelling JR; Constantiner M; Iyengar SK; Sedor JR
    Kidney Int; 2000 Oct; 58(4):1742-50. PubMed ID: 11012908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early deficits in insulin secretion, beta cell mass and islet blood perfusion precede onset of autoimmune type 1 diabetes in BioBreeding rats.
    Medina A; Parween S; Ullsten S; Vishnu N; Siu YT; Quach M; Bennet H; Balhuizen A; Åkesson L; Wierup N; Carlsson PO; Ahlgren U; Lernmark Å; Fex M
    Diabetologia; 2018 Apr; 61(4):896-905. PubMed ID: 29209740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials.
    Greenbaum CJ
    Clin Immunol; 2002 Aug; 104(2):97-104. PubMed ID: 12165270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
    Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
    Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-peptide used in the estimation of islet beta-cell function in diabetes.
    Gjessing HJ
    Dan Med Bull; 1992 Oct; 39(5):438-52. PubMed ID: 1424818
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical value of C-peptide determination].
    Meier C; Ladewig A; Keller U; Berger W
    Praxis (Bern 1994); 1997 Aug; 86(34):1289-95. PubMed ID: 9381016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.